Ampio Pharmaceuticals Inc. short interest in 2022
In 2022, Ampio Pharmaceuticals Inc.'s disclosed short interest ran from 8.68% of shares outstanding on 14 Jan 2022 to 1.51% on 30 Dec 2022, a change of -7.17 percentage points. The year's high was 10.20% on 13 May 2022 and its low 1.25% on 30 Nov 2022, averaging 6.68% across 21 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 18.73 days on 28 Feb 2022. Full history: Ampio Pharmaceuticals Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024
2022 in figures
- Start of year
- 8.68% (14 Jan 2022)
- End of year
- 1.51% (30 Dec 2022)
- Change
- -7.17 pp
- High
- 10.20% (13 May 2022)
- Low
- 1.25% (30 Nov 2022)
- Average
- 6.68%
- Highest days to cover
- 18.73 (28 Feb 2022)
- SEC filings marked
- 6
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 8.68% | 16.86 | |
| 31 Jan 2022 | 7.93% | 13.46 | |
| 15 Feb 2022 | 7.92% | 16.23 | |
| 28 Feb 2022 | 8.25% | 18.73 | |
| 15 Mar 2022 | 7.97% | 7.82 | |
| 31 Mar 2022 | 9.07% | 4.28 | 10-K filed, results (8-K) |
| 14 Apr 2022 | 10.06% | 14.14 | |
| 29 Apr 2022 | 10.06% | 3.57 | |
| 13 May 2022 | 10.20% | 10.52 | |
| 31 May 2022 | 8.81% | 5.28 | 10-Q filed, results (8-K) |
| 15 Jun 2022 | 8.86% | 4.52 | |
| 30 Jun 2022 | 5.76% | 1.54 | |
| 15 Jul 2022 | 5.75% | 4.78 | |
| 29 Jul 2022 | 5.62% | 5.35 | |
| 15 Aug 2022 | 5.04% | 1.24 | 10-Q filed |
| 31 Aug 2022 | 5.33% | 1.40 | |
| 15 Sep 2022 | 5.31% | 1.00 | |
| 30 Sep 2022 | 5.30% | 1.90 | |
| 30 Nov 2022 | 1.25% | 1.00 | 10-Q filed |
| 15 Dec 2022 | 1.50% | 1.00 | |
| 30 Dec 2022 | 1.51% | 1.03 |
See also: Ampio Pharmaceuticals Inc.'s full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.